LM103 vaccine with PD-1 for advanced solid tumors
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor like melanoma, cervical cancer, ovarian cancer, head and neck cancer, non-small cell lung cancer, or esophageal cancer that has not responded to standard treatments.
- You are expected to live at least 3 more months.
- You are well enough to carry out daily activities (ECOG 0 or 1).
- You have at least one tumor that can be safely biopsied or surgically removed to make the vaccine.
- You have at least one other tumor that can be measured on scans to see if the treatment works.
- You have not had certain other cancers in the last 5 years (except easily treated ones like some skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests LM103 in people with advanced solid cancers that have not responded to standard treatments or where standard options are not suitable. It mainly focuses on whether LM103 can be safely given and whether it can shrink tumors or help control the disease.
This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
This Phase I/II study tests LM-101, a new injection, in adults with advanced solid cancers that have already been treated and kept growing. It aims to see how safe it is and whether it can shrink tumors or help people live longer.
Hear when a new Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.